Pneumonia in children: symptoms and treatment tactics

Pneumonia in children is an acute infectious disease of the lower respiratory tract involving the lung parenchyma, characterized by fever, cough, tachypnea, signs of respiratory failure, and infiltrates on radiographs or computed tomography (CT) in the presence of a compatible clinical picture. Viruses and Streptococcus pneumoniae are the most common etiologies in preschool-aged children; Mycoplasma pneumoniae and Chlamydia pneumoniae are also common in schoolchildren. A distinction is made between community-acquired and hospital-acquired pneumonia, as well as pneumonia associated with the provision of medical care, which influences the empirical choice of therapy and the specifics of examination. In most cases, timely treatment leads to a full recovery; however, with late diagnosis, complications involving the pleura and bronchopulmonary tissue are possible. [1]

In recent years, the approach to managing pediatric pneumonia has shifted toward early initiation of antibacterial therapy when a bacterial cause is suspected, shorter courses in uncomplicated cases, strict de-escalation, and an emphasis on supportive measures. NICE guidelines, updated in 2025, recommend initiating antibiotics within the first 4 hours of admission when the diagnosis is established and reconsidering the need for investigations and the duration of courses to the minimum required. For children with mild community-acquired pneumonia, microbiological testing is not routinely required, which reduces unnecessary prescriptions and treatment delays. At the same time, the role of dynamic reassessment after 48-72 hours is emphasized. [2]

At the same time, clarifications regarding oxygen support and the use of biomarkers in hospitalized patients have emerged. In a hospital setting, monitoring C-reactive protein or procalcitonin on days 3-4 is acceptable if there is any doubt about the effectiveness of therapy, without substituting laboratory "numbers" for clinical assessment. In children with severe pneumonia, oxygen therapy is indicated for hypoxemia; target thresholds and delivery methods are selected individually based on the clinical presentation. This helps reduce the length of stay and the number of invasive interventions. [3]

Despite advances in vaccination and improved outpatient care, pneumonia remains the leading cause of infectious death in children worldwide, particularly in resource-limited settings. According to WHO and partners, pneumonia accounts for a significant proportion of deaths in children under 5 years of age, with most deaths potentially preventable through immunization, adequate nutrition, early diagnosis, and timely administration of first-line antibacterial agents. These global benchmarks are also important for clinical practice at the individual level. [4]

Code according to ICD-10 and ICD-11

In the International Classification of Diseases, Tenth Revision, pneumonia is coded in the range J12-J18: viral pneumonia (J12), pneumonia caused by Streptococcus pneumoniae (J13), Haemophilus influenzae (J14), other bacterial pneumonias (J15), pneumonia of other etiology (J16), pneumonia in diseases classified elsewhere (J17), and pneumonia of unspecified pathogen (J18). In pediatric practice, J18.0 "bronchopneumonia, unspecified" and J18.9 "pneumonia of unspecified pathogen" are often used, and in cases of obvious triggers, codes for specific pathogens are used. The choice of code depends on the confirmation data and the clinical situation. [5]

In the International Classification of Diseases, Eleventh Revision, pneumonia is classified under the "Lung Infections" (CA40) category, which includes the CA40 core category "Pneumonia" and subcategories (e.g., CA40.Z "Pneumonia, Unspecified Agent"). ICD-11 supports post-coordination, allowing for the addition of details (type of pathogen, setting of occurrence—community-acquired or hospital-acquired, severity). This coding provides better opportunities for monitoring and quality of care. [6]

Table 1. Codes for pneumonia according to ICD-10 and ICD-11

Classification	Range/category	Code examples	Comment
ICD-10	J12-J18	J12 - viral; J13 - pneumococcal; J14 - Haemophilus influenzae; J18 - unspecified pathogen	Please check the code based on the survey data.
ICD-10	J18.*	J18.0, J18.1, J18.9	Common codes in initial management
ICD-11	CA40	CA40 - "Pneumonia"	Basic heading "lung infections"
ICD-11	CA40.Z	Pneumonia, pathogen unspecified	Post-coordination (etiology, context) is possible

Epidemiology

Pneumonia remains the leading cause of infectious death in children under 5 years of age globally. WHO estimates that pneumonia accounted for approximately 14% of all deaths in children under 5 years of age in 2019 (approximately 740,180 cases), with the highest burden remaining in South Asia and sub-Saharan Africa. UNICEF data show that pneumonia deaths in this age group have declined by approximately 54% since 2000, but progress has slowed since 2015. These figures highlight the importance of prevention strategies and equitable access to care. [7]

Incidence varies by age and vaccination status: children under 24 months have the highest risk, which declines with immune maturation and coverage with pneumococcal conjugate vaccines. According to Asian cohorts, the overall incidence of community-acquired pneumonia in children under 5 years of age may reach approximately 130 per 1,000 person-years; in Europe and Latin America, estimates are lower but retain a pronounced seasonality. These differences reflect demographics, respiratory virus circulation, and vaccination coverage. [8]

Seasonality in children is pronounced: peaks occur during the cold season in temperate latitudes and during periods of high circulation of respiratory viruses. Increases in atypical bacterial etiologies associated with Mycoplasma pneumoniae have been noted in certain years; in 2024, a number of countries recorded an increase in hospitalizations associated with Mycoplasma pneumoniae in children compared to 2018-2023. This undulation requires flexibility in empirical regimens and a willingness to add macrolides to schoolchildren with an "atypical" phenotype. [9]

At the healthcare system level, standards for early treatment initiation and rational use of antibiotics are important to simultaneously improve outcomes and contain antimicrobial resistance. The updated NICE 2025 guidelines and "antibiotic stewardship" initiatives outline specific thresholds for initiating therapy, approaches to microbiological diagnostics, and review timelines. [10]

Reasons

In preschool children, the main contributors are respiratory viruses (respiratory syncytial virus, influenza, parainfluenza, metapneumovirus, adenoviruses) and Streptococcus pneumoniae; in older children, the proportion of Mycoplasma pneumoniae and Chlamydia pneumoniae increases. The etiology is influenced by the season, epidemiological situation, and vaccination status. Bacterial-viral coinfections are common and can increase the severity of the disease. Recognizing the clinical and epidemiological pattern helps select the initial regimen. [11]

Hospital-acquired pneumonia and pneumonia in children with comorbidities are characterized by a different spectrum of pathogens, including resistant ones. Local susceptibility data and previous antibacterial therapy are important here. Premature infants and children with chronic lung diseases are more often infected with gram-negative bacilli and staphylococci, requiring expanded coverage at the outset. This justifies the distinction between community-acquired and hospital-acquired approaches. [12]

Pneumonia should be considered as a complication of viral epidemics, when the primary viral infection sets the stage for bacterial superinfection. This is why vaccination against influenza and pneumococcus reduces the risk of severe outcomes, including hospitalization. At the individual level, this reduces the need for broad empirical coverage. [13]

In children with immunodeficiencies and neuromuscular disorders, the etiologic spectrum is broader and includes opportunistic pathogens, as well as aspiration mechanisms for infiltrate formation. In such scenarios, the algorithm is expanded to include microbiological diagnostics and imaging. [14]

Risk factors

Age-related risk factors include age under 24 months, prematurity, low birth weight, and lack of breastfeeding. These periods are characterized by high hospitalization rates and the severity of clinical manifestations. The presence of older siblings attending child care also plays a role. [15]

Environmental risk factors include passive smoking in the family, overcrowded living conditions, poor ventilation, and low vaccination rates in the child's environment. These factors increase the risk of both viral and bacterial pneumonia. Modifying them is an important part of family-level prevention. [16]

Medical factors include chronic diseases (congenital heart defects, bronchopulmonary dysplasia, bronchial asthma), neurological disorders, dysphagia, and immunodeficiencies. These children are more likely to require early hospitalization, extensive diagnostics, and longer-term follow-up. Individualized vaccination plans are important for them. [17]

Epidemiological surges in Mycoplasma pneumoniae in schoolchildren and adolescents, as shown by data from 2024-2025, temporarily increase the likelihood of an "atypical" etiology. This is taken into account when choosing empirical therapy and the threshold for adding a macrolide. [18]

Table 2. Risk factors for pneumonia in children

Category	Examples	Clinical significance
Age	Up to 24 months, prematurity	More severe course and frequent hospitalizations
Wednesday	Passive smoking, overcrowding, poor ventilation	Increased incidence and relapses
Medical	Heart defects, BPD, neurology, immunodeficiency	The need for early hospitalization and advanced diagnostics
Epidemiology	The rise of Mycoplasma pneumoniae	Choosing a macrolide for schoolchildren with atypical pneumonia

Pathogenesis

Pneumonia develops when a pathogen enters the distal respiratory tract due to a deficiency of local barriers and a systemic immune response. Viruses damage the respiratory epithelium, impair mucociliary clearance, and facilitate bacterial colonization, increasing the risk of secondary bacterial pneumonia. In infants, the immaturity of the immune system and the narrowness of the airways exacerbate ventilation-perfusion mismatches. [19]

Bacterial pneumonia is characterized by alveolar exudate, leukocyte infiltration, and impaired oxygen diffusion, leading to hypoxemia and respiratory distress. Some children develop parapneumonic effusion and pleural empyema as a result of the local inflammatory response and microbial invasion of the pleural space. These mechanisms determine the radiographic appearance and the need for intervention. [20]

"Atypical" etiology (Mycoplasma pneumoniae) often produces interstitial changes and disproportionate fatigue with scant physical findings. In schoolchildren, this explains the discrepancy between clinical presentation and radiographic findings in the early stages. Confirmation of the etiology is not always possible in routine practice; therefore, it is important to choose the right empirical coverage. [21]

In children with comorbidities (neuromuscular disorders, aspiration), microaspiration and bacterial contamination mechanisms predominate in the pathogenesis, necessitating an emphasis on aspiration prevention, nutritional correction, and respiratory rehabilitation. Understanding the specific pathogenesis helps to more precisely target treatment. [22]

Symptoms

The classic pediatric presentation includes fever, cough, tachypnea, and chest retractions. In young children, this may also include a refusal to drink, lethargy, decreased appetite, and episodes of apnea. Schoolchildren are more likely to experience chest pain when breathing and coughing, shortness of breath during exertion, and general weakness. The severity of symptoms depends on age and the pathogen. [23]

Objectively, attention is paid to respiratory rate, oxygen saturation, signs of respiratory work (nasal flaring, groaning exhalation), auscultatory wheezing, and crepitations. However, the absence of "gross" findings does not rule out pneumonia, especially with an "atypical" etiology. Therefore, an assessment of the general condition and the dynamics of symptoms is important. [24]

In some children, gastrointestinal symptoms (nausea, vomiting, abdominal pain) predominate, which is associated with viscerosomatic reflexes and innervation characteristics. This may mask the respiratory nature of the disease and delay seeking medical attention. When combined with cough and fever, pneumonia should be considered. [25]

In severe cases, signs of hypoxemia (cyanosis, dyspnea at rest), impaired hemodynamics, and impaired consciousness appear, requiring immediate hospitalization and oxygen support. Certain complications (pleural empyema, lung abscess) manifest as persistent fever and pain, requiring further evaluation. [26]

Classification, forms and stages

Based on the conditions of infection, a distinction is made between community-acquired and hospital-acquired pneumonia. Community-acquired pneumonia develops outside the hospital or within the first 48 hours of hospitalization; hospital-acquired pneumonia develops after 48 hours of hospitalization or later, as well as after recent discharge. This distinction determines the likely pathogens and the initial antibacterial strategy. [27]

Based on etiology, viral, bacterial, atypical, and mixed forms are distinguished. In young children, viral and pneumococcal variants predominate, while in schoolchildren, the proportion of Mycoplasma pneumoniae increases. Etiological classification is important for selecting initial treatment and prognosis. [28]

The severity of the disease is assessed based on clinical findings: respiratory rate, oxygen saturation, respiratory function, hemodynamics, and ability to drink and take oral medications. The presence of severe symptoms and comorbidities lowers the hospitalization threshold. For inpatients, step-by-step criteria for stabilization and transition to oral therapy are used. [29]

The management phase is divided into the initial suspicion phase (clinical and epidemiological findings), confirmation phase (radiography/CT scan as indicated, minimally sufficient tests), treatment phase with subsequent de-escalation, and outcome monitoring phase. Routine "control radiography" is not required for children without clinical indications. [30]

Table 3. Practical classification of pneumonia in children

Sign	Options	Clinical significance
Context	Outpatient, hospital	Different pool of pathogens and empiricism
Etiology	Viral, bacterial, atypical, mixed	Selecting a treatment regimen
Heaviness	Light, medium, heavy	Decision on hospitalization/ICU
Stage of management	Suspicion → confirmation → treatment → control	Route standardization

Complications and consequences

The most common complications are parapneumonic effusion and pleural empyema, which require drainage and extended antibacterial therapy. Less common are lung abscess and necrotizing pneumonia associated with staphylococcal etiology, which require expanded coverage and a multidisciplinary approach. Timely diagnosis of complications reduces the risk of long-term disability. [31]

In cases of recurrent or severe illness without recovery between episodes, congenital airway anomalies, aspiration, immunodeficiencies, and cystic fibrosis should be excluded. Undiagnosed comorbidities perpetuate the "vicious cycle" of infections, and treatment proves insufficient. This justifies in-depth diagnostic testing as indicated. [32]

Long courses and repeated hospitalizations increase the risk of antibiotic resistance and adverse events. This is why current guidelines advocate short but sufficient courses, de-escalation, and narrow-spectrum drugs for stable dynamics. This approach improves the sustainability of healthcare systems. [33]

With adequate therapy and the absence of complications, children fully recover and return to normal activity. Residual changes in lung function are rare and are usually associated with severe underlying conditions or late presentation. Regular relapse prevention and vaccinations maintain success. [34]

When to see a doctor

Signs of respiratory failure require immediate attention: frequent shortness of breath at rest, chest wall retractions, cyanosis, a "groaning" exhalation, oxygen saturation below normal target values, severe lethargy, and refusal to drink. These are indications for hospital evaluation and possible oxygen support. Parents should be aware of these "red flags." [35]

Consult a doctor if fever persists for more than 3 days with a cough, if symptoms worsen despite treatment, if fever recurs after a period of improvement, or if chest and abdominal pain develops with a cough. These scenarios may indicate complications or the ineffectiveness of empiric treatment. Early reassessment allows for appropriate adjustments to the treatment plan. [36]

Children with comorbidities (heart defects, bronchopulmonary dysplasia, neurological disorders, immunodeficiencies) and infants in their first year of life are given a lower threshold for hospitalization. Here, the decision is made more broadly to prevent decompensation. Access to 24-hour medical services is essential. [37]

It's helpful for parents to have written instructions on how to administer fever-reducing medications, when to return to the doctor, and how to monitor breathing, fluid intake, and urination. Such reminders reduce rehospitalizations and improve treatment adherence. [38]

Table 4. Red Flags for Immediate Action

Sign	Why is it important?
Dyspnea at rest, retractions, cyanosis	Risk of respiratory failure
Saturation below target values	Indications for oxygen/hospitalization
Refusal to drink, infrequent urination	Risk of dehydration
Recurrence of fever, increased pain	Possible complications

Diagnostics

The first step is a clinical assessment: who should be suspected of having pneumonia, who requires observation, and who requires hospitalization. The doctor determines the respiratory rate, oxygen saturation, and work of breathing, auscultates the lungs, and assesses the general condition. At this stage, a decision is made about initiating antibiotics if a bacterial cause is suspected and whether oxygen is needed. Delaying therapy if the condition is clearly present is not justified. [39]

The second step is minimally adequate testing. Routine microbiological testing is not recommended for children with mild community-acquired pneumonia; chest X-ray is necessary if the diagnosis is in doubt, the disease progresses severely, complications are suspected, or there is no improvement. Blood tests (complete blood count, inflammatory markers) are performed clinically; their changes are nonspecific and are interpreted in context. This approach reduces diagnostic overload. [40]

The third step is extensive diagnostic testing in hospitalized patients: blood cultures as indicated, collection of diagnostic material when possible (e.g., sputum in older children), and viral testing during outbreak seasons if this affects treatment strategy. In severely ill patients, C-reactive protein or procalcitonin levels may be monitored on days 3-4 if there are concerns about treatment effectiveness. Decisions are made in a multidisciplinary manner. [41]

The fourth step is visualization of complications. If parapneumonic effusion is suspected, an ultrasound examination of the pleural cavity is performed; in complex cases, a computed tomography scan is performed. Repeat radiography after clinical recovery is not routinely indicated. The entire algorithm is focused on safety and adequacy, without redundant examinations. [42]

Table 5. Diagnostic steps for pneumonia in a child

Stage	What are we doing?	When is it necessary?
Clinic	Assessment of breathing, saturation, severity	Always when in doubt
Base	Radiography as indicated; minimum tests	Severe course, complications, no improvement
Microbiology	Blood cultures, sputum (if possible), viral panels	Hospitalization, severe cases, ineffectiveness
Control	Re-evaluation in 48-72 hours	No expected improvement

Differential diagnosis

A simple viral lower respiratory tract infection can mimic early pneumonia, but often resolves without infiltrates on imaging and without significant hypoxemia. When in doubt, follow-up is important: if improvement occurs within 48-72 hours with symptomatic treatment, the likelihood of bacterial pneumonia is low. This avoids unnecessary antibiotics. [43]

Bronchial asthma and obstructive bronchitis cause wheezing and cough, but typically have significant symptom variability and a good response to bronchodilators and inhaled glucocorticosteroids. Pneumonia is more often associated with fever, localized crepitations, and infiltrates on chest radiographs. In controversial cases, the decision is made based on a combination of data. [44]

Tuberculosis infection, bronchial foreign bodies, aspiration pneumonia, and rare interstitial lung diseases in children require targeted investigations in cases of atypical presentation, relapses, or lack of response to treatment. This involves enhanced imaging, specific tests, and the involvement of specialized specialists. This prevents chronicity and complications. [45]

In cases of persistent or recurrent fever with chest pain associated with pneumonia, pleural complications (effusion, empyema) and staphylococcal etiology, which is associated with necrotizing forms, must be excluded. Pleural ultrasound and adjustment of the antibacterial regimen are key here. [46]

Table 6. Differential landmarks

State	What does it "suggest"?	How do we confirm this?
Viral bronchiolitis/bronchitis	Improvement in 48-72 hours without antibiotics	Clinic, sometimes viral tests
Asthma	Variability in response to bronchodilators	Peak flowmetry, bronchodilator test
Tuberculosis	Contacts, persistent cough, weight loss	Diagnostic tests for tuberculosis, X-ray/CT
Aspiration/foreign body	Sudden attack, local wheezing	X-ray/CT, bronchoscopy

Treatment

The mainstay of therapy is the earliest possible initiation of antibiotics if the disease is suspected to be bacterial. NICE 2025 guidelines recommend initiating treatment within 4 hours of admission to hospital, and immediately after diagnosis in outpatient settings. For mild community-acquired cases in children, oral amoxicillin is preferred, while co-amoxicillin/clavulanate is preferred for those with an ENT phenotype and a risk of beta-lactamases. It is important to prescribe the shortest possible course of treatment, provided there is stable improvement. [47]

For school-age children with an "atypical" presentation (dry cough, low-grade fever, scant auscultatory findings, severe fatigue), a macrolide is added to aminopenicillin or the macrolide is used as monotherapy based on clinical indications. The increase in Mycoplasma pneumoniae activity in 2024 confirms the relevance of this option. Lack of response within 48-72 hours serves as a signal for reassessment and modification of the regimen. [48]

In hospitals, intravenous ampicillin or penicillin G remain first-line treatments for children without risk factors for resistance; in cases of risk factors or severe clinical presentation, co-amoxicillin or second- or third-generation cephalosporins are used. If staphylococcal or necrotizing pneumonia is suspected, coverage against methicillin-resistant Staphylococcus aureus is added according to local protocols, with mandatory de-escalation after obtaining data. Transition to an oral medication is performed after clinical stabilization. [49]

The course duration for children with uncomplicated pneumonia is increasingly being shortened: a number of current guidelines support 5-day courses for those with good progression, while the NICE draft update (April 2025) discusses a 3-day course for children aged 3-11 years with mild pneumonia (as a draft position for discussion). In any case, the decision is made by the physician based on the clinical presentation and monitoring of the patient's condition. Excessive course duration does not reduce relapses but increases the risk of adverse effects. [50]

Symptomatic therapy includes antipyretics and analgesics appropriate for age and body weight, adequate hydration, and early mobilization. Routine administration of antitussives to children is not recommended, as coughing helps clear the airways. In cases of severe obstruction, short-term use of bronchodilators "on demand" is acceptable, but this does not replace etiotropic therapy. Teaching parents nasal care techniques and creating a comfortable microclimate accelerates recovery. [51]

Oxygen support is indicated for hypoxemia: most guidelines target an oxygen saturation threshold of approximately 90-92% at rest, taking into account the clinical presentation. Low-flow nasal cannulae are used initially; in more severe cases, masks or high-flow nasal oxygen are used. The goal is to eliminate signs of respiratory distress and maintain saturation within target values, avoiding hyperoxygenation. Oxygen requirements are reassessed daily. [52]

In hospitalized patients who do not show the expected improvement by days 3–4, C-reactive protein or procalcitonin levels can be monitored as part of a comprehensive reassessment; however, therapy should not be changed based solely on laboratory parameters. Clinical progression, a decrease in respiratory rate, normalization of temperature, restoration of appetite, and a reduction in oxygen requirements are more important. This approach reduces unnecessary escalation. [53]

Pleural complications require an active approach: ultrasound verification of effusion, involvement of a thoracic surgeon, drainage of empyema, and selection of a longer antibacterial regimen with de-escalation based on pleural fluid culture results. Early identification of complications improves outcomes and reduces the length of hospital stay. Pain control and respiratory rehabilitation are essential. [54]

Discharge is possible with stable breathing without oxygen, a fever-free state for at least 48 hours, adequate fluid and nutrition intake, and the ability to take oral medications. Before discharge, the family receives a written plan, including guidelines for temperature, breathing, fluid intake, and criteria for immediate treatment. Repeat chest radiography is not routinely necessary after full clinical recovery. This "package" reduces the risk of return visits and hospitalizations. [55]

Antibiotic stewardship is an integral part of management: a narrow spectrum of antibiotics initially for typical symptoms, de-escalation as symptoms improve, shortened course duration, and the avoidance of "just in case" repeat prescriptions and prophylactic regimens outside of clear indications. This helps curb antimicrobial resistance and protects the child's microbiome. In pediatric departments, such programs have been shown to reduce unnecessary prescriptions without worsening outcomes. [56]

Table 7. Summary of treatment tactics

Situation	First line	Alternatives/Supplements	Duration with dynamics
Outpatient, preschooler	Amoxicillin orally	Co-amoxicillin for ENT background	Often 5 days
Schoolboy, "atypical"	Macrolide ± amoxicillin	Review in 48-72 hours	Individually
Inpatient care without risks	Ampicillin/penicillin G	Co-amoxicillin/cephalosporins	5-7 days for uncomplicated cases
Complications (empyema)	Antibiotic + drainage	De-escalation by culture	Longer, in the clinic

Prevention

Vaccination is the primary preventative measure: pneumococcal conjugate vaccines administered according to the national schedule, as well as seasonal influenza vaccination when indicated, significantly reduce the incidence of severe outcomes and hospitalizations. Immunization of the child's immediate environment further reduces the circulation of respiratory pathogens. The effectiveness of vaccination has been confirmed by epidemiological observations. [57]

Non-specific measures include avoiding passive smoking, maintaining adequate ventilation and humidification, reducing crowding, and practicing hand hygiene during seasonal increases in respiratory infections. These simple steps reduce the risk of illness and alleviate the course of existing infections. They are especially important for young children and children with comorbidities. [58]

Nutrition and breastfeeding play an important role in protecting infants from severe infections. Supporting breastfeeding, correcting deficiencies, and normalizing body weight increase resistance to infection and improve recovery from pneumonia. Nutritional support is part of a comprehensive approach. [59]

Individualized prevention plans are being developed for children with chronic illnesses, including early contact with a physician when symptoms appear, a low threshold for hospitalization, and a plan to prevent aspiration in patients with dysphagia and neuromuscular disorders. This reduces the incidence of relapses and severe outcomes. [60]

Forecast

With timely diagnosis and appropriate treatment, the prognosis for most children is favorable: clinical recovery occurs within 1-2 weeks, with functional recovery occurring slightly later. Reversal of radiographic changes may lag behind clinical signs and does not require routine monitoring if the patient feels well. Return to normal physical activity is permissible based on how well the patient feels. [61]

An unfavorable prognosis is associated with severe complications (empyema, necrotizing pneumonia), late presentation, comorbidities, and lack of vaccination. In such cases, the duration of hospitalization and the risk of prolonged restrictions increase. A multidisciplinary approach and early intervention improve outcomes. [62]

At the population level, childhood pneumonia mortality continues to decline, but the rate varies across regions. Efforts to expand immunization, improve access to first-line antibiotics, and improve primary care remain key to achieving child health goals. This is consistent with UNICEF and partner reports. [63]

After uncomplicated pneumonia, most children do not experience long-term limitations. Recurring episodes require investigation of anatomical and immune causes and adjustments to prophylaxis. This pragmatic approach minimizes future risks. [64]

FAQ

Do all children with pneumonia require antibiotics?
No. Viral pneumonias are treated supportively; antibiotics are indicated when a bacterial cause is suspected. In outpatient practice, routine microbiological testing is not required for children with mild community-acquired pneumonia, and therapy is initiated clinically, with subsequent reassessment after 48–72 hours. [65]

What is the optimal course duration?
For uncomplicated community-acquired pneumonia in children, 5 days is increasingly sufficient if there is stable improvement; the NICE update is discussing a 3-day course for some children aged 3-11 years with mild symptoms (currently in the consultation phase). The final decision will be based on clinical evaluation and follow-up. [66]

When is hospitalization necessary?
In cases of respiratory failure, significant work of breathing, oxygen saturation below target levels, dehydration, inability to take oral medications, the presence of serious comorbidities, or in infancy. Also, if there is no improvement despite appropriate therapy. [67]

Are repeat x-rays dangerous?
Routine "control" images are unnecessary after complete clinical recovery. X-rays or other imaging modalities are performed based on indications: complications, atypical progression, or lack of improvement. This reduces radiation exposure and does not worsen outcomes. [68]